Morphine News and Research

Latest Morphine News and Research

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

Spring fever not an official medical condition

In the season of ducklings, blooming dogwoods and open-toed sandals, some people are struck with a mysterious malady - spring fever.

24 Apr 2010

Calmare pain therapy medical device reviewed at CTT's annual meeting of shareholders

Competitive Technologies, Inc. held its annual meeting of shareholders today at the Hilton Stamford Hotel and Executive Meeting Center in Stamford, Conn. John B. Nano, CTT's Chairman, President and CEO reviewed the company's performance and highlighted the exciting progress on its sales and distribution plan for its Calmare pain therapy medical device, and other selected technologies.

20 Apr 2010

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.

15 Apr 2010

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies, Inc. announced today that Thomas J. Smith, MD FACP, and co-investigator Patrick J. Coyne, MSN, APRN, FAAN, of Virginia Commonwealth University's Massey Cancer Center have completed their open Phase II clinical study examining CTT's Calmare pain therapy medical device's efficacy treating patients suffering with severe pain from chemotherapy induced peripheral neuropathy.

15 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

Critical experts introduce mild exercise programs to care critically ill patients in ICU

A new report from critical care experts at Johns Hopkins shows that use of prescription sedatives goes down by half so that mild exercise programs can be introduced to the care of critically ill patients in the intensive care unit.

9 Apr 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Radio ad supports legislation to end cash for egg donation

Today, Family Research Council Action and the Oklahoma Family Policy Council released a radio advertisement supporting State Representative Rebecca Hamilton's Oklahoma House Bill 3077, currently being reviewed by the Oklahoma State Senate. H.B. 3077 would put an end to the financial lure that draws young women into donating their eggs to fertility clinics, a dangerous procedure that can cause life-threatening complications including kidney failure and blood clots.

27 Mar 2010

Two EMBEDA video news releases misleading, warns FDA DDMAC

On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.

27 Mar 2010

CHF applauds Congress and the President for introducing universal health care coverage

Children's Health Fund strongly supports the reconciliation bill signed by President Barack Obama implementing positive changes and fixes to the health reform bill he signed earlier this week. This second piece of health reform legislation marks an unprecedented effort to make real and positive change for the health and well-being of children in this country.

27 Mar 2010

DEA crackdown on nursing home drugs comes under Congressional scrutiny

The New York Times previews a Capitol Hill hearing Wednesday where nursing home operators and caregivers will criticize a narcotics crackdown by the Drug Enforcement Administration that they say "has left seriously ill patients crying for pain relief.

25 Mar 2010

Virginia-based medical practice implements CTT's pain therapy medical device

Competitive Technologies, Inc. announced that a premier physician oncology practice based in Virginia has begun using CTT's Calmare® Therapy pain therapy medical device to treat patients suffering from pain related to cancer, under the direction of several medical oncologists.

24 Mar 2010

Arizona eliminates CHIP; Schwarzenegger seeks to reform California prison health care system

The New York Times: "Arizona on Thursday became the first state to eliminate its Children's Health Insurance Program when Gov. Jan Brewer signed an austere budget that will leave nearly 47,000 low-income children without coverage." The state's budget woes are a stark depiction of "how the fiscal crisis afflicting state governments is cutting deeply into health care.

20 Mar 2010

Alpharma to pay $42.5M for settling alleged Kadian kickback scheme

Alpharma Inc. has agreed to pay $42.5 million to the federal government and certain states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller.

18 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

False Claims Act allegations over marketing of morphine-based drug Kadian: Alpharma to pay $42.5M

American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain.

17 Mar 2010

Azur Pharma to acquire PRIALT analgesic therapy from Elan Pharmaceuticals

Azur Pharma Limited today announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion).

12 Mar 2010

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

The manufacturers of Fentanyl Transdermal Systems, in collaboration with Health Canada, would like to inform Canadians of important new changes made to the Dose Conversion Guidelines in the Product Monograph. These guidelines are used to help determine what dosage of Fentanyl Transdermal Systems is appropriate for each individual patient.

11 Mar 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010

Morphine News and Research

Latest Morphine News and Research

Stinging FDA review for Acurox – the implications

Spring fever not an official medical condition

Calmare pain therapy medical device reviewed at CTT's annual meeting of shareholders

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies to introduce Calmare pain therapy at medical conference

Critical experts introduce mild exercise programs to care critically ill patients in ICU

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

Radio ad supports legislation to end cash for egg donation

Two EMBEDA video news releases misleading, warns FDA DDMAC

CHF applauds Congress and the President for introducing universal health care coverage

DEA crackdown on nursing home drugs comes under Congressional scrutiny

Virginia-based medical practice implements CTT's pain therapy medical device

Arizona eliminates CHIP; Schwarzenegger seeks to reform California prison health care system

Alpharma to pay $42.5M for settling alleged Kadian kickback scheme

Genes allowing opium poppy to make codeine and morphine discovered

False Claims Act allegations over marketing of morphine-based drug Kadian: Alpharma to pay $42.5M

Azur Pharma to acquire PRIALT analgesic therapy from Elan Pharmaceuticals

New changes made to the Dose Conversion Guidelines on Fentanyl Transdermal Systems

KAPIDEX to be marketed as DEXILANT in the U.S.

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Morphine News and Research

Latest Morphine News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in